Archive: 1/12/2016

In cancer immunotherapy, one PD-L1 test to rule them all?

Clinical trials have proven the power of immunotherapies targeting PD-L1 or PD-1 in a range of cancers. However, these same trials show that only some patients benefit - tumors must depend on PD-L1 to be affected when medicines ...

page 1 from 10